70 phenotypes from 11 alleles in 15 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Tg(Tek-cre)1Ywa/0 Thbdtm2Rdr/Thbdtm2Wlr involves: 129S2/SvPas * C57BL/6 * SJL	abnormal acute phase protein level	J:71269
	abnormal blood coagulation	J:71269
	abnormal liver morphology	J:71269
	abnormal lung morphology	J:71269
	abnormal placental thrombosis	J:71269
	abnormal thrombosis	J:71269
	cardiac fibrosis	J:71269
	decreased body size	J:71269
	decreased body weight	J:71269
	embryonic lethality during organogenesis, incomplete penetrance	J:71269
	enlarged heart	J:71269
	gastrointestinal hemorrhage	J:71269
	hematuria	J:71269
	hemothorax	J:71269
	increased circulating D-dimer level	J:71269
	increased circulating interleukin-6 level	J:71269
	increased heart right ventricle weight	J:71269
	increased heart weight	J:71269
	increased megakaryocyte cell number	J:71269
	increased spleen weight	J:71269
	intracerebral hemorrhage	J:71269
	lethality throughout fetal growth and development, incomplete penetrance	J:71269
	liver hemorrhage	J:71269
	lung hemorrhage	J:71269
	pallor	J:71269
	premature death	J:71269
	priapism	J:71269
	pulmonary hypertension	J:71269
	skin hemorrhage	J:71269
	slow postnatal weight gain	J:71269
	thrombocytopenia	J:71269
Thbdtm1(THBD)Sltz/Thbd+ either: 129S/SvEv-Thbdtm1(THBD)Sltz or (involves: 129S/SvEv * C57BL/6)	abnormal enzyme/coenzyme activity	J:191461
Thbdtm1(THBD)Sltz/Thbdtm1(THBD)Sltz 129S/SvEv-Thbdtm1(THBD)Sltz	abnormal enzyme/coenzyme activity	J:191461
	preweaning lethality, incomplete penetrance	J:191461
Thbdtm1(THBD)Sltz/Thbdtm1(THBD)Sltz involves: 129S/SvEv * C57BL/6	abnormal enzyme/coenzyme activity	J:191461
	lethality during fetal growth through weaning, incomplete penetrance	J:191461
Thbdtm1.1(KOMP)Vlcg/Thbd+ C57BL/6N-Thbdtm1.1(KOMP)Vlcg/Ucd	increased lung weight	J:211773
Thbdtm1.1(KOMP)Vlcg/Thbdtm1.1(KOMP)Vlcg C57BL/6N-Thbdtm1.1(KOMP)Vlcg/Ucd	embryonic lethality prior to organogenesis	J:211773
	preweaning lethality, complete penetrance	J:211773
Thbdtm1.1(THBD)Sltz/Thbd+ either: 129S/SvEv(FVB)-Thbdtm1.1(THBD)Sltz or B6.129S(FVB)-Thbdtm1.1(THBD)Sltz	abnormal enzyme/coenzyme activity	J:191461
Thbdtm1.1(THBD)Sltz/Thbdtm1.1(THBD)Sltz 129S/SvEv(FVB)-Thbdtm1.1(THBD)Sltz	abnormal enzyme/coenzyme activity	J:191461
	preweaning lethality, incomplete penetrance	J:191461
Thbdtm1.1(THBD)Sltz/Thbdtm1.1(THBD)Sltz B6.129S(FVB)-Thbdtm1.1(THBD)Sltz	abnormal enzyme/coenzyme activity	J:191461
	abnormal response to injury	J:191461
	lethality during fetal growth through weaning, incomplete penetrance	J:191461
Thbdtm1.1Hlwu/Thbdtm1.1Hlwu Lyz2tm1(cre)Ifo/Lyz2+ B6.129-Thbdtm1.1Hlwu Lyz2tm1(cre)Ifo	decreased circulating interleukin-6 level	J:188879
	decreased circulating tumor necrosis factor level	J:188879
	decreased susceptibility to bacterial infection	J:188879
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:188879
	decreased susceptibility to induced morbidity/mortality	J:188879
	decreased susceptibility to injury	J:188879
	decreased tumor necrosis factor secretion	J:188879
Thbdtm1Emc/Thbdtm1Emc involves: 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal circulating protein level	J:54997
	normal homeostasis/metabolism phenotype	J:54997
Thbdtm1Rdr/Thbd+ involves: 129S2/SvPas	no abnormal phenotype detected	J:22630
Thbdtm1Rdr/Thbdtm1Rdr involves: 129S2/SvPas	abnormal embryonic tissue morphology	J:22630
	abnormal endocardium morphology	J:22630
	abnormal heart development	J:22630
	embryonic growth arrest	J:22630
	embryonic lethality during organogenesis, complete penetrance	J:22630
Thbdtm1Wlr/Thbdtm1Wlr B6.129S2-Thbdtm1Wlr	abnormal blood coagulation	J:111502
	abnormal heart morphology	J:111502
	abnormal kidney morphology	J:111502
	abnormal lung morphology	J:111502
	abnormal spleen morphology	J:111502
	decreased circulating tumor necrosis factor level	J:111502
	increased circulating D-dimer level	J:111502
	increased circulating interleukin-1 beta level	J:111502
	increased circulating interleukin-6 level	J:111502
	increased susceptibility to endotoxin shock	J:111502
	increased susceptibility to induced morbidity/mortality	J:111502
	increased susceptibility to induced thrombosis	J:111502
Thbdtm1Wlr/Thbdtm2Rdr involves: 129S2/SvPas * C57BL/6	abnormal blood coagulation	J:111502
	abnormal heart morphology	J:47676, J:111502
	abnormal lung morphology	J:47676, J:111502
	abnormal lung thrombosis	J:47676
	abnormal spleen morphology	J:47676, J:111502
	increased circulating D-dimer level	J:111502
	increased susceptibility to induced thrombosis	J:111502
Thbdtm2.1Emc/Thbdtm2.1Emc involves: 129/Sv * BALB/c * C57BL/6	abnormal leukocyte adhesion	J:118000
	abnormal leukocyte physiology	J:118000
	increased circulating interleukin-1 beta level	J:118000
	increased circulating tumor necrosis factor level	J:118000
	increased myocardial infarct size	J:118000
	increased susceptibility to endotoxin shock	J:118000
Thbdtm2Emc/Thbdtm2Emc either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte physiology	J:118000
	increased susceptibility to induced morbidity/mortality	J:118000
Thbdtm2Rdr/Thbdtm2Rdr involves: 129S2/SvPas * C57BL/6	abnormal placenta development	J:82224
	abnormal trophoblast layer morphology	J:82224
	decreased trophoblast giant cell number	J:82224
	embryonic growth arrest	J:74855, J:82224
	embryonic lethality, complete penetrance	J:74855
	small ectoplacental cone	J:82224